Aerie Pharmaceuticals, Inc. (AERI) Given a $68.00 Price Target at JMP Securities
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) received a $68.00 price target from stock analysts at JMP Securities in a report issued on Wednesday. The firm presently has a “buy” rating on the stock. JMP Securities’ target price suggests a potential upside of 5.75% from the company’s previous close.
Several other equities analysts have also recently issued reports on the company. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $62.00 price target on shares of Aerie Pharmaceuticals in a report on Wednesday. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Cowen and Company reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. Finally, Mizuho reiterated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $67.46.
Shares of Aerie Pharmaceuticals (AERI) traded up 16.17% during midday trading on Wednesday, reaching $64.30. 3,761,665 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $54.52 and a 200-day moving average of $50.51. The company’s market capitalization is $2.34 billion. Aerie Pharmaceuticals has a 1-year low of $32.05 and a 1-year high of $65.89.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02. Equities analysts expect that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP bought a new position in shares of Aerie Pharmaceuticals during the 1st quarter valued at about $107,000. Ameritas Investment Partners Inc. bought a new position in shares of Aerie Pharmaceuticals during the 1st quarter valued at about $108,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after purchasing an additional 3,579 shares in the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Aerie Pharmaceuticals during the 1st quarter valued at about $202,000. Finally, Amalgamated Bank bought a new position in shares of Aerie Pharmaceuticals during the 2nd quarter valued at about $204,000. Hedge funds and other institutional investors own 94.64% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.